daunorubicin has been researched along with niacinamide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Darling, IM; Kamath, AV; Morris, ME | 1 |
| Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ | 1 |
| Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
| Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ | 1 |
| Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
1 review(s) available for daunorubicin and niacinamide
| Article | Year |
|---|---|
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
1 trial(s) available for daunorubicin and niacinamide
| Article | Year |
|---|---|
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
4 other study(ies) available for daunorubicin and niacinamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Choline uptake in human intestinal Caco-2 cells is carrier-mediated.
Topics: Caco-2 Cells; Carrier Proteins; Choline; Daunorubicin; Humans; Intestinal Mucosa; Intestines; Kinetics; Membrane Transport Proteins; Niacinamide; Sodium; Tetraethylammonium; Time Factors; Verapamil | 2003 |
[Effect of sorafenib combined with daunorubicin on K562 cell line].
Topics: Apoptosis; Benzenesulfonates; Daunorubicin; Drug Synergism; Humans; K562 Cells; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation | 2013 |